Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response
OBJECTIVEThere is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of...
Gespeichert in:
Veröffentlicht in: | AIDS (London) 2021-11, Vol.35 (13), p.2119-2127 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2127 |
---|---|
container_issue | 13 |
container_start_page | 2119 |
container_title | AIDS (London) |
container_volume | 35 |
creator | Corma-Gómez, Anaïs Macías, Juan Téllez, Francisco Morano, Luis Rivero, Antonio Serrano, Miriam Ríos, María José Vera-Méndez, Francisco Jesús Santos, Marta Real, Luis Miguel Palacios, Rosario Santos, Ignacio de Los Geijo, Paloma Imaz, Arkaitz Merino, Dolores Galindo, Maria José Reus-Bañuls, Sergio López-Ruz, Miguel Ángel Galera, Carlos Pineda, Juan A. |
description | OBJECTIVEThere is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of liver-related events appearance in this setting. DESIGNA multicentric prospective cohort study. METHODSHCV-monoinfected and HIV/HCV-coinfected patients from GEHEP-011 cohort, whose inclusion criteria were had achieved SVR with DAA-based therapy; liver stiffness prior to starting treatment at least 9.5 kPa; and available liver stiffness measurement at SVR. SVR was considered as the baseline time-point. RESULTSOne thousand and thirty-five patients were included, 664 (64%) coinfected with HIV. Before DAA-based therapy, 63 (6.1%) individuals showed decompensated cirrhosis. After SVR, 51 (4.9%) patients developed liver complications. Median (Q1-Q3) time to the emergence of hepatic events was hepatic encephalopathy 11 (7-24) months, ascites 14 (6-29) months, hepatocellular carcinoma (HCC) 17 (11-42) months and portal hypertension gastrointestinal bleeding (PHGB) 28 (22-38) months (P = 0.152). We define two profiles of liver complications: those emerging earlier (encephalopathy and ascites) and, those occurring continuously during the follow-up (HCC, PHGB) [median (Q1-Q3) time to emergence 12.7 (6.6-28.2) months vs. 25.4 (12.5-41.53) months, respectively (P = 0.026)]. CONCLUSIONThe vast majority of HCV-infected patients who develop liver complications after reaching SVR with DAA do it within 3 years after SVR time-point. Specifically, hepatic encephalopathy and ascites do not usually emerge after this period. Conversely, HCC and PHGB may occur in longer term. It is critical to identify patients at risk of developing hepatic events to continue performing surveillance for them. |
doi_str_mv | 10.1097/QAD.0000000000002959 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2534617588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2534617588</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3296-1606fdf01ee44c3b794711e2efb502b80d8ad217ead9f4326cb30c9f717abcc43</originalsourceid><addsrcrecordid>eNpdUU1P3DAQtaoidQv8Aw4-9kCoP5I4PqLtB6hICAm4Ro49Zg3eOLWdXfVn9R_WYStR1ZfxzLx5b0YPoTNKLiiR4vPd5ZcL8s9jspHv0IrWgldNI-h7tCKslZXkgnxAH1N6LqCGdN0K_f7hRshOJxwshi3EJxg1LIl3O4hYh-3knVbZhTFhN-INTCXJLuE13rk4L0ULOoPBSwPGnLAaDVZmpwqTwdYNMSSXzvHe5c1rb_mEOeOr68dKh8N84T_HyuaimeaUVVnLLALBh6ei73GENJUd4AQdWeUTnP6Nx-jh29f79VV1c_v9en15U2nOZFvRlrTWWEIB6lrzQchaUAoM7NAQNnTEdMowKkAZaWvOWj1woqUVVKhB65ofo08H3imGnzOk3G9d0uC9GiHMqWcNr1sqmq4r0PoA1eXSFMH2U3RbFX_1lPSLQ31xqP_fobexffDl7vTi5z3EfgPK580rnBFOKkYYpZRQUi2llv8BvSSX_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2534617588</pqid></control><display><type>article</type><title>Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Corma-Gómez, Anaïs ; Macías, Juan ; Téllez, Francisco ; Morano, Luis ; Rivero, Antonio ; Serrano, Miriam ; Ríos, María José ; Vera-Méndez, Francisco Jesús ; Santos, Marta ; Real, Luis Miguel ; Palacios, Rosario ; Santos, Ignacio de Los ; Geijo, Paloma ; Imaz, Arkaitz ; Merino, Dolores ; Galindo, Maria José ; Reus-Bañuls, Sergio ; López-Ruz, Miguel Ángel ; Galera, Carlos ; Pineda, Juan A.</creator><creatorcontrib>Corma-Gómez, Anaïs ; Macías, Juan ; Téllez, Francisco ; Morano, Luis ; Rivero, Antonio ; Serrano, Miriam ; Ríos, María José ; Vera-Méndez, Francisco Jesús ; Santos, Marta ; Real, Luis Miguel ; Palacios, Rosario ; Santos, Ignacio de Los ; Geijo, Paloma ; Imaz, Arkaitz ; Merino, Dolores ; Galindo, Maria José ; Reus-Bañuls, Sergio ; López-Ruz, Miguel Ángel ; Galera, Carlos ; Pineda, Juan A.</creatorcontrib><description>OBJECTIVEThere is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of liver-related events appearance in this setting. DESIGNA multicentric prospective cohort study. METHODSHCV-monoinfected and HIV/HCV-coinfected patients from GEHEP-011 cohort, whose inclusion criteria were had achieved SVR with DAA-based therapy; liver stiffness prior to starting treatment at least 9.5 kPa; and available liver stiffness measurement at SVR. SVR was considered as the baseline time-point. RESULTSOne thousand and thirty-five patients were included, 664 (64%) coinfected with HIV. Before DAA-based therapy, 63 (6.1%) individuals showed decompensated cirrhosis. After SVR, 51 (4.9%) patients developed liver complications. Median (Q1-Q3) time to the emergence of hepatic events was hepatic encephalopathy 11 (7-24) months, ascites 14 (6-29) months, hepatocellular carcinoma (HCC) 17 (11-42) months and portal hypertension gastrointestinal bleeding (PHGB) 28 (22-38) months (P = 0.152). We define two profiles of liver complications: those emerging earlier (encephalopathy and ascites) and, those occurring continuously during the follow-up (HCC, PHGB) [median (Q1-Q3) time to emergence 12.7 (6.6-28.2) months vs. 25.4 (12.5-41.53) months, respectively (P = 0.026)]. CONCLUSIONThe vast majority of HCV-infected patients who develop liver complications after reaching SVR with DAA do it within 3 years after SVR time-point. Specifically, hepatic encephalopathy and ascites do not usually emerge after this period. Conversely, HCC and PHGB may occur in longer term. It is critical to identify patients at risk of developing hepatic events to continue performing surveillance for them.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/QAD.0000000000002959</identifier><language>eng</language><publisher>Lippincott Williams & Wilkins</publisher><ispartof>AIDS (London), 2021-11, Vol.35 (13), p.2119-2127</ispartof><rights>Lippincott Williams & Wilkins</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3296-1606fdf01ee44c3b794711e2efb502b80d8ad217ead9f4326cb30c9f717abcc43</citedby><cites>FETCH-LOGICAL-c3296-1606fdf01ee44c3b794711e2efb502b80d8ad217ead9f4326cb30c9f717abcc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Corma-Gómez, Anaïs</creatorcontrib><creatorcontrib>Macías, Juan</creatorcontrib><creatorcontrib>Téllez, Francisco</creatorcontrib><creatorcontrib>Morano, Luis</creatorcontrib><creatorcontrib>Rivero, Antonio</creatorcontrib><creatorcontrib>Serrano, Miriam</creatorcontrib><creatorcontrib>Ríos, María José</creatorcontrib><creatorcontrib>Vera-Méndez, Francisco Jesús</creatorcontrib><creatorcontrib>Santos, Marta</creatorcontrib><creatorcontrib>Real, Luis Miguel</creatorcontrib><creatorcontrib>Palacios, Rosario</creatorcontrib><creatorcontrib>Santos, Ignacio de Los</creatorcontrib><creatorcontrib>Geijo, Paloma</creatorcontrib><creatorcontrib>Imaz, Arkaitz</creatorcontrib><creatorcontrib>Merino, Dolores</creatorcontrib><creatorcontrib>Galindo, Maria José</creatorcontrib><creatorcontrib>Reus-Bañuls, Sergio</creatorcontrib><creatorcontrib>López-Ruz, Miguel Ángel</creatorcontrib><creatorcontrib>Galera, Carlos</creatorcontrib><creatorcontrib>Pineda, Juan A.</creatorcontrib><title>Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response</title><title>AIDS (London)</title><description>OBJECTIVEThere is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of liver-related events appearance in this setting. DESIGNA multicentric prospective cohort study. METHODSHCV-monoinfected and HIV/HCV-coinfected patients from GEHEP-011 cohort, whose inclusion criteria were had achieved SVR with DAA-based therapy; liver stiffness prior to starting treatment at least 9.5 kPa; and available liver stiffness measurement at SVR. SVR was considered as the baseline time-point. RESULTSOne thousand and thirty-five patients were included, 664 (64%) coinfected with HIV. Before DAA-based therapy, 63 (6.1%) individuals showed decompensated cirrhosis. After SVR, 51 (4.9%) patients developed liver complications. Median (Q1-Q3) time to the emergence of hepatic events was hepatic encephalopathy 11 (7-24) months, ascites 14 (6-29) months, hepatocellular carcinoma (HCC) 17 (11-42) months and portal hypertension gastrointestinal bleeding (PHGB) 28 (22-38) months (P = 0.152). We define two profiles of liver complications: those emerging earlier (encephalopathy and ascites) and, those occurring continuously during the follow-up (HCC, PHGB) [median (Q1-Q3) time to emergence 12.7 (6.6-28.2) months vs. 25.4 (12.5-41.53) months, respectively (P = 0.026)]. CONCLUSIONThe vast majority of HCV-infected patients who develop liver complications after reaching SVR with DAA do it within 3 years after SVR time-point. Specifically, hepatic encephalopathy and ascites do not usually emerge after this period. Conversely, HCC and PHGB may occur in longer term. It is critical to identify patients at risk of developing hepatic events to continue performing surveillance for them.</description><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUU1P3DAQtaoidQv8Aw4-9kCoP5I4PqLtB6hICAm4Ro49Zg3eOLWdXfVn9R_WYStR1ZfxzLx5b0YPoTNKLiiR4vPd5ZcL8s9jspHv0IrWgldNI-h7tCKslZXkgnxAH1N6LqCGdN0K_f7hRshOJxwshi3EJxg1LIl3O4hYh-3knVbZhTFhN-INTCXJLuE13rk4L0ULOoPBSwPGnLAaDVZmpwqTwdYNMSSXzvHe5c1rb_mEOeOr68dKh8N84T_HyuaimeaUVVnLLALBh6ei73GENJUd4AQdWeUTnP6Nx-jh29f79VV1c_v9en15U2nOZFvRlrTWWEIB6lrzQchaUAoM7NAQNnTEdMowKkAZaWvOWj1woqUVVKhB65ofo08H3imGnzOk3G9d0uC9GiHMqWcNr1sqmq4r0PoA1eXSFMH2U3RbFX_1lPSLQ31xqP_fobexffDl7vTi5z3EfgPK580rnBFOKkYYpZRQUi2llv8BvSSX_g</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Corma-Gómez, Anaïs</creator><creator>Macías, Juan</creator><creator>Téllez, Francisco</creator><creator>Morano, Luis</creator><creator>Rivero, Antonio</creator><creator>Serrano, Miriam</creator><creator>Ríos, María José</creator><creator>Vera-Méndez, Francisco Jesús</creator><creator>Santos, Marta</creator><creator>Real, Luis Miguel</creator><creator>Palacios, Rosario</creator><creator>Santos, Ignacio de Los</creator><creator>Geijo, Paloma</creator><creator>Imaz, Arkaitz</creator><creator>Merino, Dolores</creator><creator>Galindo, Maria José</creator><creator>Reus-Bañuls, Sergio</creator><creator>López-Ruz, Miguel Ángel</creator><creator>Galera, Carlos</creator><creator>Pineda, Juan A.</creator><general>Lippincott Williams & Wilkins</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20211101</creationdate><title>Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response</title><author>Corma-Gómez, Anaïs ; Macías, Juan ; Téllez, Francisco ; Morano, Luis ; Rivero, Antonio ; Serrano, Miriam ; Ríos, María José ; Vera-Méndez, Francisco Jesús ; Santos, Marta ; Real, Luis Miguel ; Palacios, Rosario ; Santos, Ignacio de Los ; Geijo, Paloma ; Imaz, Arkaitz ; Merino, Dolores ; Galindo, Maria José ; Reus-Bañuls, Sergio ; López-Ruz, Miguel Ángel ; Galera, Carlos ; Pineda, Juan A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3296-1606fdf01ee44c3b794711e2efb502b80d8ad217ead9f4326cb30c9f717abcc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Corma-Gómez, Anaïs</creatorcontrib><creatorcontrib>Macías, Juan</creatorcontrib><creatorcontrib>Téllez, Francisco</creatorcontrib><creatorcontrib>Morano, Luis</creatorcontrib><creatorcontrib>Rivero, Antonio</creatorcontrib><creatorcontrib>Serrano, Miriam</creatorcontrib><creatorcontrib>Ríos, María José</creatorcontrib><creatorcontrib>Vera-Méndez, Francisco Jesús</creatorcontrib><creatorcontrib>Santos, Marta</creatorcontrib><creatorcontrib>Real, Luis Miguel</creatorcontrib><creatorcontrib>Palacios, Rosario</creatorcontrib><creatorcontrib>Santos, Ignacio de Los</creatorcontrib><creatorcontrib>Geijo, Paloma</creatorcontrib><creatorcontrib>Imaz, Arkaitz</creatorcontrib><creatorcontrib>Merino, Dolores</creatorcontrib><creatorcontrib>Galindo, Maria José</creatorcontrib><creatorcontrib>Reus-Bañuls, Sergio</creatorcontrib><creatorcontrib>López-Ruz, Miguel Ángel</creatorcontrib><creatorcontrib>Galera, Carlos</creatorcontrib><creatorcontrib>Pineda, Juan A.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Corma-Gómez, Anaïs</au><au>Macías, Juan</au><au>Téllez, Francisco</au><au>Morano, Luis</au><au>Rivero, Antonio</au><au>Serrano, Miriam</au><au>Ríos, María José</au><au>Vera-Méndez, Francisco Jesús</au><au>Santos, Marta</au><au>Real, Luis Miguel</au><au>Palacios, Rosario</au><au>Santos, Ignacio de Los</au><au>Geijo, Paloma</au><au>Imaz, Arkaitz</au><au>Merino, Dolores</au><au>Galindo, Maria José</au><au>Reus-Bañuls, Sergio</au><au>López-Ruz, Miguel Ángel</au><au>Galera, Carlos</au><au>Pineda, Juan A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response</atitle><jtitle>AIDS (London)</jtitle><date>2021-11-01</date><risdate>2021</risdate><volume>35</volume><issue>13</issue><spage>2119</spage><epage>2127</epage><pages>2119-2127</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>OBJECTIVEThere is scarce available evidence on the distribution over time of liver complications emergence in hepatitis C virus (HCV)-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral (DAA)-based therapy. Therefore, we aimed at describing the kinetics of liver-related events appearance in this setting. DESIGNA multicentric prospective cohort study. METHODSHCV-monoinfected and HIV/HCV-coinfected patients from GEHEP-011 cohort, whose inclusion criteria were had achieved SVR with DAA-based therapy; liver stiffness prior to starting treatment at least 9.5 kPa; and available liver stiffness measurement at SVR. SVR was considered as the baseline time-point. RESULTSOne thousand and thirty-five patients were included, 664 (64%) coinfected with HIV. Before DAA-based therapy, 63 (6.1%) individuals showed decompensated cirrhosis. After SVR, 51 (4.9%) patients developed liver complications. Median (Q1-Q3) time to the emergence of hepatic events was hepatic encephalopathy 11 (7-24) months, ascites 14 (6-29) months, hepatocellular carcinoma (HCC) 17 (11-42) months and portal hypertension gastrointestinal bleeding (PHGB) 28 (22-38) months (P = 0.152). We define two profiles of liver complications: those emerging earlier (encephalopathy and ascites) and, those occurring continuously during the follow-up (HCC, PHGB) [median (Q1-Q3) time to emergence 12.7 (6.6-28.2) months vs. 25.4 (12.5-41.53) months, respectively (P = 0.026)]. CONCLUSIONThe vast majority of HCV-infected patients who develop liver complications after reaching SVR with DAA do it within 3 years after SVR time-point. Specifically, hepatic encephalopathy and ascites do not usually emerge after this period. Conversely, HCC and PHGB may occur in longer term. It is critical to identify patients at risk of developing hepatic events to continue performing surveillance for them.</abstract><pub>Lippincott Williams & Wilkins</pub><doi>10.1097/QAD.0000000000002959</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-9370 |
ispartof | AIDS (London), 2021-11, Vol.35 (13), p.2119-2127 |
issn | 0269-9370 1473-5571 |
language | eng |
recordid | cdi_proquest_miscellaneous_2534617588 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
title | Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T23%3A41%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Kinetics%20of%20emergence%20of%20liver%20complications%20in%20hepatitis%20C%20virus%20infected%20patients%20and%20advanced%20fibrosis,%20with%20and%20without%20HIV-coinfection,%20after%20sustained%20virological%20response&rft.jtitle=AIDS%20(London)&rft.au=Corma-G%C3%B3mez,%20Ana%C3%AFs&rft.date=2021-11-01&rft.volume=35&rft.issue=13&rft.spage=2119&rft.epage=2127&rft.pages=2119-2127&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/QAD.0000000000002959&rft_dat=%3Cproquest_cross%3E2534617588%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2534617588&rft_id=info:pmid/&rfr_iscdi=true |